Andrea De Giglio: The prognostic role of STK11 mutations in advanced NSCLC treated with first-line IO
Andrea De Giglio, Junior Assistant Professor at University of Bologna, posted on X about recent paper by him as first author, titled “STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status” published on Lung Cancer.
Authors: Andrea De Giglio, Dario De Biase, Valentina Favorito, Thais Maloberti, Alessandro Di Federico, Federico Zacchini, Giulia Venturi, Claudia Parisi, Filippo Gustavo Dall’Olio, Ilaria Ricciotti, Ambrogio Gagliano, Barbara Melotti, Francesca Sperandi, Annalisa Altimari, Elisa Gruppioni, Giovanni Tallini, Francesco Gelsomino, Lorenzo Montanaro, Andrea Ardizzoni.
“Our study in Lung Cancer Journal reveals the negative prognostic role of STK11 mutations in advanced NSCLC treated with first-line IO or Cht-IO.
Proud to collaborate with Alessandro Di Federico at University of Bologna and Sant Orsola.
STK11 mutations show a clear link with worse overall survival (OS), irrespective of treatment modality or co-mutations (KRAS, KEAP1, TP53). Findings were validated using the OAK/POPLAR datasets.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023